NY-EMENDO-BIO
17.5.2022 22:17:09 CEST | Business Wire | Press release
Emendo Biotherapeutics presented the results of its next generation CRISPR-based gene editing approaches for several indications in an oral presentation and three posters at the 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) held May 16-19, 2022, in Washington, D.C.
Emendo presented pre-clinical data for the treatment of ELANE -related Severe Congenital Neutropenia using an allele-specific editing approach, demonstrating the power of Emendo’s dual technology platforms that enable the development of a highly specific editing composition that demonstrates no off-targets and complete allele specificity. Significantly, the lack of off-target achieved by Emendo’s engineered and optimized OMNI nuclease also eliminated any translocations. Edited patient derived CD34+ cells differentiated normally into neutrophils both in-vitro and in-vivo , showing full engraftment and reconstitution of all blood lineages, as required for the desired therapeutic effect.
“ELANE -based Severe Congenital Neutropenia, Emendo’s lead indication, is a devastating disease affecting pediatric patients that until now has been incurable,” said David Baram, Ph.D., President & CEO of Emendo Biotherapeutics. “We are excited by the potentially curative treatment developed by our team and were pleased to present our pre-clinical results for this program and other diverse applications of our dual gene editing technology platforms at this year’s ASGCT meeting. And of course, we look forward to the discussion generated by our discoveries around Type II CRISPR nuclease classifications that promise to be ground-breaking in the field.”
Senior members of the Emendo Biotherapeutics R&D team including Chief Technology Officer Lior Izhar, Ph.D. and Executive Vice-President Research & Development Rafi Emmanuel, Ph.D. presented Emendo’s research on-site at the conference.
Session Presentation
Title: A Novel Engineered CRISPR-Associated Nuclease Accurately Removes ELANE Mutated Allele and Shifts HSC Differentiation Towards Neutrophils in Severe Congenital Neutropenia
Session Title: Gene Therapy for Immunologic Diseases
Session Date/Time: Tuesday May 17, 2022 3:45 PM - 5:30 PM
Presentation Time: 3:45pm - 4:00pm
Room: Room 202
Final abstract number: 482
Poster Presentations
Title: A Unique CRISPR-Based Nuclease with a Non-NGG PAM Efficiently Targets Multiple Exclusive Genomic Sites for Immuno-Oncology Based Therapy
Session Title: Cancer - Targeted Gene and Cell Therapy I
Session Date/Time: Monday May 16, 2022 5:30 PM - 6:30 PM
Poster Board Number: M-215
Room: Hall D
Final abstract number: 334
Title: CRISPR-Based Gene Editing Enhances LDLR Expression and Boosts LDL-C Uptake in Familial Hypercholesterolemia
Session Title: Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases II
Session Date/Time: Wednesday May 18, 2022 5:30 PM - 6:30 PM
Poster Board Number: W-125
Room: Hall D
Final abstract number: 999
Title: Challenges and Inconsistencies in Type II CRISPR-Associated Nuclease Subtype Classification
Session Title: Gene Targeting and Gene Correction II
Session Date/Time: Tuesday May 17, 2022 5:30 PM - 6:30 PM
Poster Board Number: Tu-61
Room: Hall D
Final abstract number: 556
About Emendo Biotherapeutics
Emendo Biotherapeutics, a subsidiary of AnGes, Inc., is a next generation CRISPR gene editing company leveraging dual proprietary technology platforms to enable high precision gene editing throughout the genome. Emendo’s novel nuclease discovery platform broadens the targetable range of the genome while its target-specific optimization platform enables highly precise editing, including allele specific editing, while maintaining high efficiencies. The capabilities of the OMNI technology platforms, along with deep expertise in genomic medicine, protein engineering and therapeutic development, provide Emendo with a unique advantage when addressing indications within hematology, oncology, ophthalmology and other disease areas. For more information please visit www.emendobio.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517006030/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Presidio Investors Expands Portfolio with Strategic Investment in Edge Home Finance21.4.2026 03:10:00 CEST | Press release
Presidio Investors ("Presidio") has completed a strategic investment in Edge Home Finance, a mortgage brokerage platform. Headquartered in Minnetonka, MN, Edge Home Finance has built a strong reputation within the mortgage broker channel by empowering loan originators and delivering best-in-class service and innovation. The investment from Presidio represents an opportunity to leverage Edge’s momentum through enhanced investments in technology, operational infrastructure, and strategic acquisitions. Edge Home Finance will continue operating with the same core platform, team, and commitment to the broker community that has fueled its success. Partner, Victor Masaya, of Presidio Investors, commented: “Edge Home Finance's platform, track record and broker-focused approach aligns perfectly with our vision of fostering excellence and growth. Together, we aim to redefine what's possible in the mortgage brokerage channel and deliver an unparalleled value proposition to loan originators." Edge
Rigaku Enters Strategic Alliance with Onto Innovation through 27 % Equity Investment21.4.2026 01:14:00 CEST | Press release
Expanding Semiconductor Opportunities through X-ray, Optical, and AI Integration Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), a global leader in X-ray analytical technologies, today announced that it has entered into a strategic capital and business alliance with Onto Innovation Inc. (headquarters: Massachusetts, USA; CEO: Michael P. Plisinski; “Onto Innovation”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420467739/en/ Double Logo “As semiconductor devices become more complex, particularly with the increasing importance of three-dimensional structures, Rigaku has been seeking to enhance its analytical capabilities by incorporating advanced model-based and AI-driven algorithms in optical metrology,” said Jun Kawakami, President and CEO, Rigaku Holdings Corporation. “Onto Innovation not only brings strong expertise in optical technologies and software, but also
Grid Dynamics Scales Hyper-Personalization for Galeries Lafayette; Drives 7% Revenue Increase via AI-Powered Search and Merchandising20.4.2026 22:05:00 CEST | Press release
Key Takeaways: Galeries Lafayette achieved a 7% total revenue increase and an 8% rise in average basket value by replatforming its legacy search and recommendation stack with Google Vertex AI Search for Commerce and Grid Dynamics' proprietary Merchandising Experience Platform (MXP). The solution successfully modernized a complex catalog of over 600,000 products—including 350,000 from third-party marketplaces—contributing to a 20% year-over-year increase in online sales. This successful program showcases Grid Dynamics’ expertise in bridging the gap between advanced AI models and measurable retail profitability for global enterprises. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, today announced the successful deployment of a hyper-personalized digital shopping experience for Galeries Lafayette, the iconic French department store. By integrating Google Vertex AI Search for Commerce with the proprietary Grid Dynami
Lattice Collaborates with TI to Accelerate Edge AI for Robotics and Industrial Applications20.4.2026 22:00:00 CEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that the company is collaborating with Texas Instruments (TI) to simplify sensor integration and to scale real-time edge AI systems. The combination of TI’s sensing technologies and the Lattice Holoscan Sensor Bridge solution, based on Lattice low power FPGA technology, will provide developers with a flexible hardware foundation for synchronized, low latency sensor data pipelines in advanced robotics and industrial applications. The collaboration demonstrates a real-time AI sensor fusion architecture that integrates TI mmWave radar and camera sensors using NVIDIA Holoscan Sensor Bridge running on Lattice’s low power FPGA. The FPGA acts as a companion chip delivering synchronized sensor data directly into GPU-accessible memory to enable low latency and robust perception for robotics and industrial edge AI applications. “As edge AI systems scale, developers need flexible platforms that simplify senso
Inspirit Capital to Acquire Kaplan Languages Group20.4.2026 17:15:00 CEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, is pleased to announce its plans to acquire KLG Kaplan Languages Group (“KLG”), a leading global language education platform, from Kaplan. All conditions for the sale have been met, and completion is due to take place on 1 May. KLG comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Since 2006, KLG has provided high-quality language education, supporting students in achieving their language goals through academic excellence, cultural immersion, and life-changing experiences. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. This next phase of ownership will also see the development of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. Paul Youens, Investment Director, Inspirit Capital: “KLG has built a st
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom